跳至主要内容
临床试验/NCT01133821
NCT01133821已完成4 期

Acute Psychotherapy for Bipolar II Depression

Holly Swartz1 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
92
试验地点
1
主要终点
Remission

研究概览

简要总结

This proposed study is designed to compare the efficacy of interpersonal and social rhythm therapy (IPSRT) alone to IPSRT plus medication as an acute treatment for bipolar II depression. The investigators propose to conduct a randomized, controlled, trial comparing the effects of IPSRT plus pill placebo to IPSRT plus quetiapine on depressive symptoms in individuals suffering from Bipolar II depression. The investigators will also examine the impact of treatment on psychosocial function.

详细描述

Specifically, we will enroll 160 individuals meeting DSM-IV criteria for BP II disorder, currently depressed, and randomly assign them to 20 weeks of treatment with IPSRT plus placebo (IPSRT-PLA) (N=80) or IPSRT plus quetiapine (IPSRT-QUE) (N=80). We will evaluate potential moderators of response to treatment including circadian phase preference, intercurrent hypomanic symptoms during the index depressive episode, clinical and demographic factors (i.e, number of previous episodes, family history of mood disorders), and prior treatment response to antidepressant medications.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults age 18 - 65
  • Meets criteria for bipolar II disorder, currently in an episode of major depression, as defined by the DSM-IV (American Psychiatric Association, 1994) and documented by the use of the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID-I), and by a rating of >15 on the 17-item Hamilton Rating Scale for Depression (HRSD-17)
  • Ability and willingness to give informed, written consent.
  • Subjects may participate in this study if they are currently taking psychotropic medications at time of informed consent. They will remain in the study (and be randomized) if they still meet eligibility criteria after a one week wash-out period.

排除标准

  • Severe or poorly controlled concurrent medical disorders that may cause confounding depressive symptoms (i.e., untreated hypothyroidism or lupus) or require medication(s) that could cause depressive symptoms (i.e., high doses of beta blockers or alpha interferon)
  • Meets criteria for one of the following concurrent DSM-IV psychiatric disorders: any psychotic or organic mental disorder, bipolar I disorder, current alcohol or drug dependence, primary obsessive compulsive disorder or primary eating disorders. (primary refers to the diagnosis associated with the most functional impairment); borderline personality disorder; antisocial personality disorder
  • Acute suicidal or homicidal ideation or requiring psychiatric hospitalization. Subjects who require inpatient treatment will be excluded (or discontinued) from the study and referred to one of WPIC's inpatient mood disorder units, or, if preferred, to an inpatient facility nearer to the patient's home
  • Severe cognitive deficits that would preclude treatment with psychotherapy and/or prevent completion of study questionnaires
  • Non-fluent in English. Subjects must be able to speak and understand English because one of the study interventions, IPSRT, is an experimental talk-therapy. This therapy cannot practically be translated.
  • Current participation in another form of individual psychotherapy. Concurrent participation in couples therapy, peer support groups (such as Alcoholics Anonymous), or family therapy will be permitted
  • Prior lack of response to a trial of at least 12 weeks of IPSRT conducted by a certified therapist
  • Prior lack of response to at least 6 weeks of 300 mg of quetiapine
  • Currently pregnant or planning to become pregnant during the trial

研究组 & 干预措施

Placebo

Placebo Comparator

Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.

干预措施: IPSRT plus placebo (IPSRT-PLA) (Drug)

IPSRT plus quetiapine

Experimental

Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel). This condition will be called IPSRT-QUE.

干预措施: IPSRT plus quetiapine (Drug)

结局指标

主要结局

Remission

时间窗: 20 weeks

Number of Remitted Participants (defined as 3 consecutive weeks with HRSD-17≤8 and YMRS≤8)

次要结局

  • Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)-Short Form(20 weeks)

研究者

发起方
Holly Swartz
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Holly Swartz

Professor of Psychiatry

University of Pittsburgh

研究点 (1)

Loading locations...

相似试验